Neurocrine Biosciences Unveils First Expert Consensus Guidelines for Managing Tardive Dyskinesia in Long-Term Care Settings Neurocrine Biosciences, Inc. today announced the presentation of the first expert consensus recommendations focused on screening, diagnosis and treatment of tardive dyskinesia among older adults in…
Abcuro Highlights Phase 2/3 MUSCLE Study Results of Ulviprubart in Inclusion Body Myositis at GCOM 2026 Abcuro, Inc. has announced new clinical data from its Phase 2/3 MUSCLE study evaluating ulviprubart (ABC008), an investigational monoclonal antibody therapy for inclusion body…
Biocytogen Announces U.S. Food and Drug Administration IND Clearance for Partner NEOK Bio’s NEOK002 in Solid Tumor Indications Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has announced a significant regulatory milestone achieved by its partner, NEOK Bio, Inc., highlighting continued progress in…
Pet Partners and Baxter Foundation Expand Therapy Animal Programs to Reach 100,000 Patients and Healthcare Workers in Two-Year Pilot Pet Partners and the Baxter Foundation, the charitable arm of Baxter International Inc., have announced a new partnership aimed at expanding…
Ono Pharma Files Application in Japan for Ripretinib (DCC-2618) to Treat Advanced Gastrointestinal Stromal Tumors Ono Pharmaceutical, headquartered in Osaka, Japan, under the leadership of President Toichi Takino, has announced the submission of a regulatory application in Japan for the…
WuXi Biologics Announces Record-Breaking Financial Performance for Fiscal Year 2025 WuXi Biologics has reported a year of strong financial performance and operational expansion for the fiscal year ending December 31, 2025, underscoring its growing influence as a leading global contract…
AbbVie Becomes Official Pharmaceutical Partner of Major League Baseball AbbVie has unveiled a landmark multi-year partnership with Major League Baseball (MLB), officially naming the company as the league’s “Official Pharmaceutical Partner” beginning with the 2026 season. This collaboration represents a…
Bristol Myers Squibb Strengthens Position in Obstructive Hypertrophic Cardiomyopathy with New Camzyos (mavacamten) Data Presented at ACC 2026 Bristol Myers Squibb has unveiled an extensive body of new clinical and real-world evidence supporting the continued evolution of Camzyos (mavacamten) as…
KalVista Pharmaceuticals to Showcase New Clinical Data on EKTERLY® (Sebetralstat) at the 2026 Global Angioedema Leadership Conference KalVista Pharmaceuticals has announced a significant scientific presence at the upcoming 2026 Global Angioedema Leadership Conference, highlighting its continued commitment to advancing treatment…
Bristol Myers Squibb Redefines First-Line Treatment Landscape in Classical Hodgkin Lymphoma with Expanded U.S. and EU Approvals for Opdivo® (nivolumab) Bristol Myers Squibb today announced that Opdivo® (nivolumab) has received approval for two new classical Hodgkin Lymphoma (cHL) indications in the U.S.…
Board Reconstitution at Genmab A/S Accompanied by Employee Grants of Restricted Stock Units and Warrants Genmab A/S has announced key governance updates and employee incentive decisions following the conclusion of its Annual General Meeting (AGM) held on March 19, 2026.…
TALZENNA in Combination with XTANDI Shows Marked Improvement in Radiographic Progression-Free Survival for Patients with Metastatic Prostate Cancer Pfizer Inc. has announced compelling topline results from its Phase 3 TALAPRO-3 clinical trial, marking a potentially significant advancement in the treatment…